Multiple Sclerosis Clinical Trials in Boston, Massachusetts

13 studies are recruiting for multiple sclerosis in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

   This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital Cancer Center, Boston, Massachusetts

   Locations

   52 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03816345 on ClinicalTrials.gov

2. A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

   The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting

   Stage

   Not phased

   Ages

   18 and older

   Site

   TG Therapeutics Investigational Trial Site, Boston, Massachusetts

   Locations

   109 in total

   Run by

   TG Therapeutics, Inc.

   See if you can join NCT06433752 on ClinicalTrials.gov

3. Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

   The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining …

   Stage

   Phase 3

   Ages

   25 to 75

   Site

   MGH Institute of Health Professions, Boston, Massachusetts

   Run by

   MGH Institute of Health Professions

   See if you can join NCT06136728 on ClinicalTrials.gov

4. A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

   The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.

   Stage

   Phase 2

   Ages

   18 to 55

   Site

   Boston Clinical Trials Inc - Internal Medicine, Boston, Massachusetts

   Locations

   17 in total

   Run by

   ModernaTX, Inc.

   See if you can join NCT06735248 on ClinicalTrials.gov

5. Genes and Environment in Multiple Sclerosis

   The purpose of the research study is to identify the genetic, environmental and immune profiles that may increase a person's risk of developing multiple sclerosis (MS). While MS is not a disease caused by a single variation in genetic material (DNA), a single environmental factor, or a single malfu…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   5 in total

   Run by

   Columbia University

   See if you can join NCT01353547 on ClinicalTrials.gov

6. Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis

   This study will evaluate the influence of sleep apnea on clinical and radiological features of MS. Sleep apnea is associated with hypoxemia during sleep, which is likely detrimental to MS. Clinical data (MRI, lab results, medical history, labs, and sleep studies) of MS patients will be collected an…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Beth Israel Deaconess Medical Center, Boston, Massachusetts

   Run by

   Beth Israel Deaconess Medical Center

   See if you can join NCT04603196 on ClinicalTrials.gov

7. Care in Multiple Sclerosis (MS)

   This study is structured around three main aims. In Aim 1, investigators will conduct community-based participatory research (CBPR) to develop culturally tailored methods to assess childhood adversity in multiple sclerosis (MS). Aim 2 will investigate the impact of childhood adversity on MS outcome…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   6 in total

   Run by

   NYU Langone Health

   See if you can join NCT07011914 on ClinicalTrials.gov

8. Molecular Imaging of NET Using [C-11]MRB-PET in MS

   This study aims to use [C-11]MRB PET (positron emission tomography) imaging to look at brain injury in patients with Multiple Sclerosis (MS) and healthy individuals. The overarching hypothesis is that there is decreased radioligand binding to the norepinephrine transporter in multiple sclerosis, re…

   Stage

   Phase 1

   Ages

   18 to 60

   Site

   Brigham MS Center, 60 Fenwood Road, Boston, Massachusetts

   Run by

   Brigham and Women's Hospital

   See if you can join NCT03207464 on ClinicalTrials.gov

9. PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

   The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by Fluorine-18 (18F) labeled "Peripheral Benzodiazepine Receptor 06" (PBR06) -PET, in subjects with active Relapsing Remitting Multiple Sclerosis (RRMS), Secondary …

   Stage

   Phase 1

   Ages

   18 to 85

   Site

   Brigham MS Center, 60 Fenwood Road, Boston, Massachusetts

   Run by

   Brigham and Women's Hospital

   See if you can join NCT02649985 on ClinicalTrials.gov

10. Assessment of Synaptic Density in MS

    The investigators propose to use the novel SV2a-PET ligand, [F-18]SDM-8 to assess synaptic density in progressive multiple sclerosis (PMS) (including primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS)), given its improved imaging characteristics and po…

    Stage

    EARLY_Phase 1

    Ages

    18 to 60

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Run by

    Brigham and Women's Hospital

    See if you can join NCT04634994 on ClinicalTrials.gov

11. Glucose Consumption in MS Using [F-18]FDG-PET

    Given the need for better diagnostic imaging techniques in multiple sclerosis (MS), the study aims to investigate the utility of [F-18]FDG positron emission tomography (PET) in MS. The study will be assessing glucose consumption patterns in subjects with progressive MS (PMS) and relapsing-remitting…

    Stage

    Phase 4

    Ages

    18 to 70

    Site

    Brigham & Women's Hospital, Boston, Massachusetts

    Run by

    Brigham and Women's Hospital

    See if you can join NCT07087106 on ClinicalTrials.gov

12. Vascular Mechanisms, Functional Outcomes, & Exercise Among Persons With Multiple Sclerosis With Hypertension

    The goal of this study is to determine if 12 weeks of cycling exercise training at home will improve three parameters: 1) blood pressure, 2) cognition, and 3) walking ability among persons with multiple sclerosis who have high blood pressure, when compared to a group that engages in a 12-week home-…

    Stage

    Not phased

    Ages

    18 and older

    Site

    UMass Boston, Boston, Massachusetts

    Run by

    University of Massachusetts, Boston

    See if you can join NCT06554340 on ClinicalTrials.gov

13. Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects

    Our overall objective is to obtain an initial assessment of the potential value of using [18F]3F4AP for imaging demyelinating diseases such as multiple sclerosis: * Aim 1) Assess the safety of [18F]3F4AP in healthy volunteers and subjects with multiple sclerosis (MS). Hypothesis 1: Administration o…

    Stage

    Phase 1

    Ages

    18 to 65

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT04699747 on ClinicalTrials.gov